<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094977</url>
  </required_header>
  <id_info>
    <org_study_id>1000013836</org_study_id>
    <nct_id>NCT01094977</nct_id>
  </id_info>
  <brief_title>Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid</brief_title>
  <official_title>Blood Loss and Transfusion Requirement in Infants Treated With Tranexamic Acid Undergoing Craniosynostosis Reconstruction: A Randomized Placebo-Controlled Double Blind Study of Low and High Dose Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate whether tranexamic acid (TXA) reduces
      perioperative blood loss and transfusion requirement in infants undergoing craniosynostosis
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood loss during pediatric craniosynostosis surgery can be significant and this may be
      exacerbated by a dilutional coagulopathy. Multimodal blood conservation strategies may limit
      allogeneic transfusions, although RCTs are few and limited. It is essential to investigate
      these techniques to determine their potential to reduce allogeneic blood transfusions and
      their associated cost and morbidity.

      Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively inhibits the
      lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator. The result is
      inhibition of fibrinolysis and clot degradation.

      Recent studies in adults undergoing cardiac surgery demonstrated that people with different
      genotypes for the plasminogen activator inhibitor-1 (PAI-1) gene may have varying degrees of
      bleeding. PAI-1 inhibits the transformation of plasminogen to plasmin thereby decreasing
      plasmin-induced fibrinolysis. Thus, PAI-1 promotes clot stability and the PAI-1 polymorphism
      will affect the degree of bleeding and response to TXA during craniosynostosis surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Prior and Post Surgery</time_frame>
    <description>Blood loss will be carefully measured in sponges, suction cannisters, cell saver systems, and in the plastic pockets of surgical drapes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphism - Samples</measure>
    <time_frame>Sample will be drawn immediately after induction and prior to administration of study drug</time_frame>
    <description>PAI-1 promotes clot stability and the PAI-1 polymorphism will affect the degree of bleeding and response to TXA during craniosynostosis surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboelastography (TEG)Sample</measure>
    <time_frame>Baseline, immediately after bolus dose of TXA is infused</time_frame>
    <description>TEG monitors coagulation of blood samples in vitro to produce a complete picture of clot formation, strength and dissolution (i.e. fibrinolysis)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Craniosynostoses</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 10 ml before skin incision and infusion according to weight until skin closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>10 mg/kg bolus with a 5 mg/kg/h infusion</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>100 mg/kg bolus with a 10 mg/kg/h infusion</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants aged 2 months to 2 years undergoing anterior cranial vault reconstruction

        Exclusion Criteria:

          -  Known bleeding disorder as this may increase the risk of bleeding

          -  Current antifibrinolytic therapy as these patients may bleed less

          -  Patient or family history of thromboembolic disease as there may be potential risk of
             thrombosis

          -  Use of NSAIDS within 5 days of surgery as this may increase the risk of bleeding

          -  Known allergy to TXA

          -  History of renal insufficiency as TXA is renally excreted

          -  Acquired colour vision defects as one of the first signs of long term TXA toxicity is
             colour vision disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara Der, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara Der, MD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>2405</phone_ext>
    <email>tara.der@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carolyne Pehora, RN</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>2406</phone_ext>
    <email>carolyne.pehora@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tara Der, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Zaarour, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Crawford, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guy Petroz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Tara Der</investigator_full_name>
    <investigator_title>Staff Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>Blood Loss and Transfusion</keyword>
  <keyword>Craniosynostoses</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Craniosynostoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

